David B Shultz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1553361/publications.pdf

Version: 2024-02-01

83	2,019	318942	286692
papers	citations	23 h-index	43 g-index

86	86	86	3597
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multidisciplinary Intervention in Radiation-Associated Angiosarcoma of the Breast: Patterns of Recurrence and Response to Treatment. Annals of Surgical Oncology, 2022, 29, 522-532.	0.7	11
2	Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neuro-Oncology Practice, 2022, 9, 50-58.	1.0	4
3	Postoperative CT scans after resection of brain metastases: neurosurgical routine or added value?. Journal of Neuro-Oncology, 2022, 157, 157-163.	1.4	2
4	ASO Visual Abstract: The Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma (RPS). Annals of Surgical Oncology, 2022, 29, 2315.	0.7	0
5	A pilot study of machine-learning based automated planning for primary brain tumours. Radiation Oncology, 2022, 17, 3.	1.2	3
6	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. Annals of Surgical Oncology, 2022, 29, 2304.	0.7	3
7	Radiological progression of extremity soft tissue sarcoma following pre-operative radiotherapy predicts for poor survival. British Journal of Radiology, 2022, 95, 20210936.	1.0	1
8	Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. Radiotherapy and Oncology, 2022, 168, 89-94.	0.3	4
9	Importance of Cobalt-60 Dose Rate and Biologically Effective Dose on Local Control for Intracranial Meningiomas Treated With Stereotactic Radiosurgery. Neurosurgery, 2022, 90, 140-147.	0.6	10
10	Multiplicity does not significantly affect outcomes in brain metastasis patients treated with surgery. Neuro-Oncology Advances, 2022, 4, vdac022.	0.4	3
11	Factors correlating with survival following adjuvant or definitive radiosurgery for large brain metastases. Neuro-Oncology, 2022, 24, 1925-1934.	0.6	4
12	Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2022, 40, 11547-11547.	0.8	1
13	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211096.	0.8	9
14	Brain Metastases: A Modern Multidisciplinary Approach. Canadian Journal of Neurological Sciences, 2021, 48, 189-197.	0.3	8
15	Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. Current Oncology, 2021, 28, 549-559.	0.9	10
16	The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.. Journal of Clinical Oncology, 2021, 39, 11548-11548.	0.8	0
17	Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. Lung Cancer, 2021, 155, 34-39.	0.9	6
18	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. Lung Cancer, 2021, 156, 76-81.	0.9	7

#	Article	IF	Citations
19	MLTI-06. Surgical resection plus stereotactic radiosurgery versus SRS alone for large brain metastases: a comparative study. Neuro-Oncology Advances, 2021, 3, iii14-iii14.	0.4	0
20	Radiation Dose Rate, Biologically Effective Dose, and Tumor Characteristics on Local Control and Toxicity After Radiosurgery for Acoustic Neuromas. World Neurosurgery, 2021, 152, e512-e522.	0.7	8
21	ASO Visual Abstract: Multidisciplinary Intervention in Radiation-Associated Angiosarcoma of the Breast: Patterns of Recurrence and Response to Treatment. Annals of Surgical Oncology, 2021, 28, 631.	0.7	1
22	The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery. Journal of Neuro-Oncology, 2021, 155, 325-333.	1.4	8
23	Resection and radiotherapy for intracranial ependymoma: a multiinstitutional 50-year experience. Journal of Neurosurgery, 2021, , 1-8.	0.9	0
24	Hyperbaric Oxygen for Radiation Necrosis of the Brain. Canadian Journal of Neurological Sciences, 2020, 47, 92-99.	0.3	19
25	A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases: Clinical Trial Protocol. Neurosurgery, 2020, 87, 403-407.	0.6	15
26	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. JAMA Oncology, 2020, 6, 567.	3.4	64
27	Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. Advances in Radiation Oncology, 2020, 5, 350-357.	0.6	12
28	Curability of patients with lymph node metastases from extremity softâ€tissue sarcoma. Cancer, 2020, 126, 5098-5108.	2.0	23
29	Reirradiation for recurrent craniopharyngioma. Advances in Radiation Oncology, 2020, 5, 1305-1310.	0.6	3
30	Patient perspectives on frame versus mask immobilization for gamma knife stereotactic radiosurgery. Journal of Medical Imaging and Radiation Sciences, 2020, 51, 567-573.	0.2	5
31	54: Re-Irradiation for Recurrent Craniopharyngioma. Radiotherapy and Oncology, 2020, 150, S26-S27.	0.3	0
32	107: Repeated Whole Brain Radiation for Small Cell Lung Cancer Patients with New, Recurrent, or Progressive Brain Metastases. Radiotherapy and Oncology, 2020, 150, S47.	0.3	0
33	Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 725-732.	1.4	42
34	Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. Annals of Surgical Oncology, 2020, 27, 2033-2041.	0.7	14
35	Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. Journal of Pain and Symptom Management, 2020, 60, 422-429.e1.	0.6	21
36	Focal Leptomeningeal Disease with Perivascular Invasion in EGFR-Mutant Non-Small-Cell Lung Cancer. American Journal of Neuroradiology, 2020, 41, 1430-1433.	1.2	2

#	Article	IF	Citations
37	Efficacy of stereotactic radiosurgery for radiation-induced meningiomas. Journal of Neuro-Oncology, 2020, 148, 299-305.	1.4	7
38	Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial. Journal of Neuro-Oncology, 2019, 142, 565-575.	1.4	42
39	Should we expand the carbon ion footprint of prostate cancer?. Lancet Oncology, The, 2019, 20, 608-609.	5.1	1
40	The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist, 2019, 24, e501-e509.	1.9	8
41	Informational needs of brain metastases patients and their caregivers. Neuro-Oncology Practice, 2019, 6, 47-60.	1.0	8
42	The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. British Journal of Radiology, 2019, 92, 20180228.	1.0	35
43	Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. Neuro-Oncology, 2019, 21, 242-251.	0.6	27
44	18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1183-1192.	0.4	22
45	Evidence-based region of interest matching guidelines for sarcoma volumetric image-guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2018, 5, 3-8.	0.6	2
46	Management and Outcomes in the Oldest-Old Population with Glioblastoma. Canadian Journal of Neurological Sciences, 2018, 45, 199-205.	0.3	10
47	Management of multiple meningiomas. Journal of Neurosurgery, 2018, 128, 1403-1409.	0.9	31
48	Neurological death in patients with EGFR-mutant non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 2062-2062.	0.8	0
49	The value of adaptive preoperative radiotherapy in management of soft tissue sarcoma. Radiotherapy and Oncology, 2017, 122, 458-463.	0.3	17
50	Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. Practical Radiation Oncology, 2017, 7, e525-e529.	1.1	9
51	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. Lancet Oncology, The, 2017, 18, e720-e730.	5.1	220
52	Hypofractionated Intensity-Modulated Radiotherapy for Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 588-594.	1.1	19
53	Early-Stage Nonâ€“Small Cell Lung Cancer: Quantitative Imaging Characteristics of¹⁸F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology, 2016, 281, 270-278.	3.6	152
54	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Radiotherapy and Oncology, 2016, 119, 454-460.	0.3	27

#	Article	IF	Citations
55	Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors. Radiation Oncology, 2016, 11, 40.	1.2	5
56	Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 808-815.	0.4	31
57	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS ONE, 2016, 11, e0147995.	1.1	13
58	Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin. Head and Neck, 2015, 37, 1102-1107.	0.9	6
59	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 568-576.	0.4	75
60	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1044-1052.	0.4	61
61	Repeat Courses of Stereotactic Radiosurgery (SRS), Deferring Whole-Brain Irradiation, forÂNew Brain Metastases After Initial SRS. International Journal of Radiation Oncology Biology Physics, 2015, 92, 993-999.	0.4	70
62	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Nonâ€“Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	3.0	64
63	Anatomic optimization of lung tumor stereotactic ablative radiation therapy. Practical Radiation Oncology, 2015, 5, e607-e613.	1.1	4
64	To SABR or Not to SABR? Indications and Contraindications for Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage, Oligometastatic, or Oligoprogressive Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2015, 25, 78-86.	1.0	20
65	Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas, 2014, 43, 777-783.	0.5	1
66	Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1426-1433.	0.5	49
67	Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure. Journal of Radiation Oncology, 2014, 3, 49-56.	0.7	2
68	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. Clinical Cancer Research, 2014, 20, 5558-5569.	3.2	64
69	Vagal and recurrent laryngeal neuropathy following stereotactic ablative radiation therapy in the chest. Practical Radiation Oncology, 2014, 4, 272-278.	1.1	15
70	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 294-301.e3.	1.1	25
71	The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. Practical Radiation Oncology, 2014, 4, 192-197.	1.1	3
72	Outcomes and toxicity of SBRT for patients with unresectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 317-317.	0.8	3

#	Article	IF	Citations
73	A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.. Journal of Clinical Oncology, 2014, 32, 4133-4133.	0.8	2
74	Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas. Laryngoscope, 2013, 123, 2675-2680.	1.1	15
75	The Optimal Use of Radiotherapy in Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 107-114.	2.3	1
76	Roles of IKK-Î², IRF1, and p65 in the Activation of Chemokine Genes by Interferon-Î³. Journal of Interferon and Cytokine Research, 2009, 29, 817-824.	0.5	37
77	Activation of a Subset of Genes by IFN-Î³ Requires IKKÎ² but Not Interferon-Dependent Activation of NF-ÎºB. Journal of Interferon and Cytokine Research, 2007, 27, 875-884.	0.5	17
78	Proinflammatory Stimuli Induce IKKÎ±-Mediated Phosphorylation of PIAS1 to Restrict Inflammation and Immunity. Cell, 2007, 129, 903-914.	13.5	145
79	Inhibitor of ÂB kinase is required to activate a subset of interferon Â-stimulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7994-7998.	3.3	60
80	Cooperation of Cytokine Signaling with Chimeric Transcription Factors in Leukemogenesis: PML-Retinoic Acid Receptor Alpha Blocks Growth Factor-Mediated Differentiation. Molecular and Cellular Biology, 2003, 23, 4573-4585.	1.1	9
81	Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor Î± Chimeric Protein (PmlrarÎ±) to Block Neutrophil Differentiation and Initiate Acute Leukemia. Journal of Experimental Medicine, 2001, 193, 531-544.	4.2	105
82	Leukemia initiated by PMLRARÎ±: the PML domain plays a critical role while retinoic acidâ€“mediated transactivation is dispensable. Blood, 2000, 95, 1541-1550.	0.6	91
83	Penetration and Co-localization in MDCK Cell Mitochondria of IgA Derived from Patients with Primary Biliary Cirrhosis. Journal of Autoimmunity, 1998, 11, 573-580.	3.0	66